Key Highlights
- Diluted earnings per share were USD 0.43 against an estimate of USD 0.52.
- Net income was USD 18.41 million, compared with USD 48.39 million.
- Nine-month Net Income was USD 134.88 million.
- Total Assets were USD 400.92 million at September 30.
Oramed Pharmaceuticals (NASDAQ:ORMP) reported third quarter 2026 Diluted Earnings per Share of USD 0.43, against an estimate of USD 0.52 and USD 1.13 in the third quarter of 2025. Basic Earnings Per Share were USD 0.44, compared with USD 1.16.
Net income was USD 18.41 million, compared with USD 48.39 million. Income before tax expenses was USD 28.28 million, compared with USD 59.45 million, and tax expenses were USD 9.87 million, compared with USD 11.06 million.
Nine-Month Results
For the nine months ended September 30, 2026, net income was USD 134.88 million, compared with USD 54.01 million. Basic income per share was USD 3.28, compared with USD 1.30, and diluted income per share was USD 3.17, compared with USD 1.26.
Income before tax expenses for the nine months was USD 179.31 million, compared with USD 65.53 million, and tax expenses were USD 44.43 million, compared with USD 11.52 million. Financial income, net, was USD 180.49 million, compared with USD 74.28 million, and other income, net, was USD 9.35 million, compared with USD 0.67 million.
Operating Expenses
Research and development expenses for the nine months decreased by 64% to approximately USD 1.59 million, compared with approximately USD 4.39 million. General and administrative expenses increased by 77% to approximately USD 8.94 million, compared with approximately USD 5.04 million. The operating loss was approximately USD 10.53 million, compared with USD 9.42 million.
For the third quarter, general and administrative expenses were USD 4.10 million, compared with USD 1.27 million, and the operating loss was USD 4.10 million, compared with USD 2.43 million.
Investments and Balance Sheet
The filing states that the Fair Value of the company's Investment in Alpha Tau ordinary shares was USD 215.74 million at September 30, 2026, compared with USD 71.62 million at December 31, 2025. It also describes Revaluation losses on Lifeward shares and warrants and on an initial note recorded in the quarter.
Cash and cash equivalents were USD 28.93 million, compared with USD 45.95 million, and marketable securities were USD 583 thousand, compared with USD 5.42 million. Investments at fair value were USD 24.25 million, compared with USD 63.55 million. Total assets were USD 400.92 million, compared with USD 230.86 million, and total stockholders' Equity was USD 339.09 million, compared with USD 199.74 million.
The filing also describes income recognized under a services agreement and related warrants, and a clinical trial management agreement under which the company charged OraTech for services and expenses and recognized a corresponding related-party receivable.
For the nine months and the quarter, respectively, the company recognized income of USD 750 thousand and USD 250 thousand under the services agreement and USD 682 thousand and USD 227 thousand in respect of the Alpha Tau warrants, totaling USD 1.43 million and USD 477 thousand, before related Investor relations expenses of USD 176 thousand and USD 68 thousand.
Oramed Pharmaceuticals Q3 2026 Earnings: Key Takeaways
Oramed Pharmaceuticals reported third quarter 2026 diluted earnings per share of USD 0.43 and net income of USD 18.41 million. Nine-month net income was USD 134.88 million, and total assets were USD 400.92 million.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...